BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 16278236)

  • 1. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
    Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective degeneration in YAC mouse models of Huntington disease.
    Van Raamsdonk JM; Warby SC; Hayden MR
    Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease.
    Carroll JB; Lerch JP; Franciosi S; Spreeuw A; Bissada N; Henkelman RM; Hayden MR
    Neurobiol Dis; 2011 Jul; 43(1):257-65. PubMed ID: 21458571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
    BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
    Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
    Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
    Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
    Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.
    Schmidt ME; Buren C; Mackay JP; Cheung D; Dal Cengio L; Raymond LA; Hayden MR
    BMC Biol; 2018 Jun; 16(1):58. PubMed ID: 29945611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Rogers DA; Bissada N; Vogl AW; Hayden MR; Leavitt BR
    Hum Mol Genet; 2005 May; 14(10):1379-92. PubMed ID: 15829505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease.
    Cho KJ; Lee BI; Cheon SY; Kim HW; Kim HJ; Kim GW
    Neuroscience; 2009 Nov; 163(4):1128-34. PubMed ID: 19646509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
    Fan J; Gladding CM; Wang L; Zhang LY; Kaufman AM; Milnerwood AJ; Raymond LA
    Neurobiol Dis; 2012 Mar; 45(3):999-1009. PubMed ID: 22198502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo.
    Graham RK; Deng Y; Pouladi MA; Vaid K; Ehrnhoefer D; Southwell AL; Bissada N; Franciosi S; Hayden MR
    J Huntingtons Dis; 2012; 1(2):243-60. PubMed ID: 25063333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.
    de Almeida LP; Ross CA; Zala D; Aebischer P; Déglon N
    J Neurosci; 2002 May; 22(9):3473-83. PubMed ID: 11978824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain.
    Van Raamsdonk JM; Metzler M; Slow E; Pearson J; Schwab C; Carroll J; Graham RK; Leavitt BR; Hayden MR
    Neurobiol Dis; 2007 Apr; 26(1):189-200. PubMed ID: 17276692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A.
    Metzler M; Gan L; Mazarei G; Graham RK; Liu L; Bissada N; Lu G; Leavitt BR; Hayden MR
    J Neurosci; 2010 Oct; 30(43):14318-29. PubMed ID: 20980587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
    Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
    J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hip14l-deficient mice develop neuropathological and behavioural features of Huntington disease.
    Sutton LM; Sanders SS; Butland SL; Singaraja RR; Franciosi S; Southwell AL; Doty CN; Schmidt ME; Mui KK; Kovalik V; Young FB; Zhang W; Hayden MR
    Hum Mol Genet; 2013 Feb; 22(3):452-65. PubMed ID: 23077216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.